1.Engineering of CRISPR-Cas12b for human genome editing.Strecker J, et al. Nature (2019) 10(1): 2122.Gene correction for SCID-X1 in long-term hematopoietic stem cells.Pavel-Dinu M, et al. Nat Commun. (2019) 10 (1): 16343.Orthotopic replacement of T-cell receptor a- and ?-chains with preservation of near-physiological T-cell function.Schober K, et al. Nat Biomed Eng (2019) 10: 014.Ribonucleoprotein Transfection for CRISPR/Cas9-Mediated Gene Knockout in Primary T Cells.Oh SA, et al. Curr Protoc Immunol (2019) 124(1): e695.Polymer-stabilized Cas9 nanoparticles and modified repair templates increase genome editing efficiency.Nguyen DN, et al. Nat Biotechnol (2019) 1: 16.CRISPR-Cas9 genome engineering of primary CD4+ T cells for the interrogation of HIV-host factor interactions. Hultquist JF, et al. Nat Protocols (2019) 14(1): 1-277.Bacteria-free minicircle DNA system to generate integration-free CAR-T cells.Chen Cheng, et al. J Med Genetics (2019) 56: 10 178.Genome-wide CRISPR Screens in Primary Human T Cells Reveal Key Regulators of Immune Function. Shifrut E, et al. Cell (2018) 175(7): 1985-19719.Guide Swap enables genome-scale pooled CRISPR-Cas9 screening in human primary cells. Ting PY, et al. Nat Methods (2018) 15(11)10.Cytokines induced killer cells produced in good manufacturing practices conditions: identification of the most advantageous and safest expansion method in terms of viability, cellular growth and identity.Castiglia S,et al.J Transl Med (2018) 16: 23711.A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells. Vakulskas CA,et al.Nat Med (2018) 24(8): 1216-122412.Reprogramming human T cell function and specificity with non-viral genome targeting.Roth TL,et al.Nature (2018) 559: 405-913.Nucleofection with Plasmid DNA for CRISPR/Cas9-Mediated Inactivation of Programmed Cell Death Protein 1 in CD133-Specific CAR T Cells.Hu B,et al.Hum Gene Ther (2018)14.Optimized RNP transfection for highly efficient CRISPR/Cas9-mediated gene knockout in primary T cells.Seki A,et al.J Exp Med (2018) 215(3): 985-99715.Improved Expansion and In Vivo Function of Patient T Cells by a Serum-free Medium.Medvec AR,et al.Mol Ther Methods Clin Dev. (2017) 7; 8: 65-7416.Going non-viral: the Sleeping Beauty transposon system breaks on through to the clinical side.Hudecek M1,et al.Clin Exp Immunol (2017) 52(4): 355(80)17.CRISPR-Mediated Integration of Large Gene Cassettes Using AAV Donor Vectors.Bak RO,et al.Cell Rep (2017) 20(3): 750-75618.CRISPR-Cas9 mediated LAG-3 disruption in CAR-T cells.Zhang Y,et al.Frontiers in Immunology (2017) 1: 1-919.CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells.Rupp LJ1,et al.Scientific Reports (2017) 7 (1): 73720.A genome-wide CRISPR screen identifies a restricted set of HIV host dependency factors.Park RJ, et al.Nat Genet (2017) 49(2): 193-203
4D-Nucleofector细胞核转系统转染RNP参考文献1. Seki A, Rutz S. Optimized RNP transfection for highly efficient CRISPR/Cas9-mediated gene knockout in primary T cells. J Exp Med. 2018 Mar 5;215(3):985-997. doi: 10.1084/jem.20171626. Epub 2018 Feb 7. PMID: 29436394; PMCID: PMC5839763.2. Oh SA, Seki A, Rutz S. Ribonucleoprotein Transfection for CRISPR/Cas9-Mediated Gene Knockout in Primary T Cells. Curr Protoc Immunol. 2019 Feb;124(1):e69. doi: 10.1002/cpim.69. Epub 2018 Oct 18. PMID: 30334617.3. Naeimi Kararoudi M, Dolatshad H, Trikha P, Hussain SA, Elmas E, Foltz JA, Moseman JE, Thakkar A, Nakkula RJ, Lamb M, Chakravarti N, McLaughlin KJ, Lee DA. Generation of Knock-out Primary and Expanded Human NK Cells Using Cas9 Ribonucleoproteins. J Vis Exp. 2018 Jun 14;(136):58237. doi: 10.3791/58237. PMID: 29985369; PMCID: PMC6101749.4. Farboud B, Jarvis E, Roth TL, Shin J, Corn JE, Marson A, Meyer BJ, Patel NH, Hochstrasser ML. Enhanced Genome Editing with Cas9 Ribonucleoprotein in Diverse Cells and Organisms. J Vis Exp. 2018 May 25;(135):57350. doi: 10.3791/57350. PMID: 29889198; PMCID: PMC6101420.5. Dewari PS, Southgate B, Mccarten K, Monogarov G, O Duibhir E, Quinn N, Tyrer A, Leitner MC, Plumb C, Kalantzaki M, Blin C, Finch R, Bressan RB, Morrison G, Jacobi AM, Behlke MA, von Kriegsheim A, Tomlinson S, Krijgsveld J, Pollard SM. An efficient and scalable pipeline for epitope tagging in mammalian stem cells using Cas9 ribonucleoprotein. Elife. 2018 Apr 11;7:e35069. doi: 10.7554/eLife.35069. PMID: 29638216; PMCID: PMC5947990.6. Daniel P. Dever1, Rasmus O. Bak1, Andreas Reinisch2, Joab Camarena1, Gabriel Washington1, Carmencita E. Nicolas1,Mara Pavel-Dinu1, Nivi Saxena1, Alec B. Wilkens1, Sruthi Mantri1, Nobuko Uchida3, Ayal Hendel1, Anupama Narla4,Ravindra Majeti2, Kenneth I. Weinberg1 Matthew H. Porteus1. CRISPR/Cas9 -globin gene targeting in human haematopoietic stem cells.2016 Springer Nature doi:10.1038 (使用4D-Nucleofector LV大规模流式核转染系统转染RNP)立即拨打13521452266，免费咨询4D-Nucleofector核转染系统技术问题+获取报价+申请试用 Lonza中国一级代理商，北京泽平
相关产品Lonza4D-Nucleofector LV大规模流式细胞核转染系统Lonza2B细胞核转染系统Lonza 4D/2b-Nucleofector 细胞核转染试剂盒Lonza X-VIVO无血清培养基、干细胞培养基、原代细胞培养基、常规培养基Lonza 人原代细胞Lonza 支原体检测、清除、预防试剂盒、Lucetta 2发光检测仪Lonza 内毒素检测试剂盒/鲎试剂、内毒素专用检测软件Lonza 琼脂糖、FlashGel闪胶系统Lonza Moda 实验室管理系统（微生物QC、制药企业专用版）
IDT Alt-R CRISPR-Cas9基因编辑系统IDTAlt-R CRISPR-Cas12a/Cpf1基因编辑系统
